1-4 of 4
R. Mark Simpson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Bih-Rong Wei, Shelley B. Hoover, Cody J. Peer, Jennifer E. Dwyer, Hibret A. Adissu, Priya Shankarappa, Howard Yang, Maxwell Lee, Tyler J. Peat, William D. Figg, R. Mark Simpson
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (11): 2308–2318.
https://doi.org/10.1158/1535-7163.MCT-19-0858
Published: 03 November 2020
View article titled, Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
Open the PDF for Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma in another window
Includes: Supplementary data
Journal Articles

Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis

Joy M. Gary, John K. Simmons, Jinfei Xu, Shuling Zhang, Tyler J. Peat, Nicholas Watson, Benjamin J. Gamache, Ke Zhang, Alexander L. Kovalchuk, Aleksandra M. Michalowski, Jin-Qiu Chen, Tuddow Thaiwong, Matti Kiupel, Snehal Gaikwad, Maudeline Etienne, R. Mark Simpson, Wendy Dubois, Joseph R. Testa, Beverly A. Mock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2221–2232.
https://doi.org/10.1158/1535-7163.MCT-19-0671
Published: 02 October 2020
View article titled, Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Open the PDF for Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis in another window
Includes: Supplementary data
Journal Articles

The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity

Ki-Eun Chang, Bih-Rong Wei, James P. Madigan, Matthew D. Hall, R. Mark Simpson, Zhengping Zhuang, Michael M. Gottesman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (1): 90–100.
https://doi.org/10.1158/1535-7163.MCT-14-0496
Published: 13 January 2015
View article titled, The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Open the PDF for The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity in another window
Includes: Supplementary data
Journal Articles

Abstract C111: Genes cooperatively targeted by combined mTOR/histone deactylase (HDAC) inhibition are predictive of increased multiple myeloma patient survival.

John K. Simmons, Jyoti Patel, Aleksandra M. Michalowski, Patrick Sullivan, Bih-Rong Wei, R. Mark Simpson, W. Michael Kuehl, Lihui Ou, Natasha J. Caplen, Shuling Zhang, C. Ola Landgren, Beverly A. Mock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C111.
https://doi.org/10.1158/1535-7163.TARG-11-C111
Published: 12 November 2011
View article titled, Abstract C111: Genes cooperatively targeted by combined mTOR/histone deactylase (HDAC) inhibition are predictive of increased multiple myeloma patient survival.